Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.

IF 4.7 2区 医学 Q1 ONCOLOGY Annual Review of Cancer Biology-Series Pub Date : 2018-03-01 Epub Date: 2017-12-01 DOI:10.1146/annurev-cancerbio-030617-050502
Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M Kass, Maria Jasin
{"title":"Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.","authors":"Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M Kass, Maria Jasin","doi":"10.1146/annurev-cancerbio-030617-050502","DOIUrl":null,"url":null,"abstract":"<p><p>Germ-line and somatic mutations in genes that promote homology-directed repair (HDR), especially <i>BRCA1</i> and <i>BRCA2</i>, are frequently observed in several cancers, in particular, breast and ovary but also prostate and other cancers. HDR is critical for the error-free repair of DNA double-strand breaks and other lesions, and HDR factors also protect stalled replication forks. As a result, loss of BRCA1 or BRCA2 poses significant risks to genome integrity, leading not only to cancer predisposition but also to sensitivity to DNA-damaging agents, affecting therapeutic approaches. Here we review recent advances in our understanding of BRCA1 and BRCA2, including how they genetically interact with other repair factors, how they protect stalled replication forks, how they affect the response to aldehydes, and how loss of their functions links to mutation signatures. Importantly, given the recent advances with poly(ADP-ribose) polymerase inhibitors (PARPi) for the treatment of HDR-deficient tumors, we discuss mechanisms by which BRCA-deficient tumors acquire resistance to PARPi and other agents.</p>","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":"2 ","pages":"313-336"},"PeriodicalIF":4.7000,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193498/pdf/nihms958408.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual Review of Cancer Biology-Series","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-cancerbio-030617-050502","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/12/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Germ-line and somatic mutations in genes that promote homology-directed repair (HDR), especially BRCA1 and BRCA2, are frequently observed in several cancers, in particular, breast and ovary but also prostate and other cancers. HDR is critical for the error-free repair of DNA double-strand breaks and other lesions, and HDR factors also protect stalled replication forks. As a result, loss of BRCA1 or BRCA2 poses significant risks to genome integrity, leading not only to cancer predisposition but also to sensitivity to DNA-damaging agents, affecting therapeutic approaches. Here we review recent advances in our understanding of BRCA1 and BRCA2, including how they genetically interact with other repair factors, how they protect stalled replication forks, how they affect the response to aldehydes, and how loss of their functions links to mutation signatures. Importantly, given the recent advances with poly(ADP-ribose) polymerase inhibitors (PARPi) for the treatment of HDR-deficient tumors, we discuss mechanisms by which BRCA-deficient tumors acquire resistance to PARPi and other agents.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
同源定向修复以及 BRCA1、BRCA2 和相关蛋白在基因组完整性和癌症中的作用。
促进同源定向修复(HDR)的基因,特别是 BRCA1 和 BRCA2,经常在几种癌症中出现种系突变和体细胞突变,尤其是乳腺癌和卵巢癌,还有前列腺癌和其他癌症。HDR 对于无差错修复 DNA 双链断裂和其他病变至关重要,HDR 因子还能保护停滞的复制叉。因此,BRCA1 或 BRCA2 的缺失会对基因组的完整性构成重大风险,不仅会导致癌症易感性,还会导致对 DNA 损伤因子的敏感性,从而影响治疗方法。在此,我们回顾了最近在了解 BRCA1 和 BRCA2 方面取得的进展,包括它们如何与其他修复因子发生基因相互作用、它们如何保护停滞的复制叉、它们如何影响对醛的反应,以及它们的功能缺失如何与突变特征相关联。重要的是,鉴于聚(ADP-核糖)聚合酶抑制剂(PARPi)在治疗HDR缺陷肿瘤方面的最新进展,我们将讨论BRCA缺陷肿瘤对PARPi和其他药物产生耐药性的机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
14.50
自引率
1.30%
发文量
13
期刊介绍: The Annual Review of Cancer Biology offers comprehensive reviews on various topics within cancer research, covering pivotal and emerging areas in the field. As our understanding of cancer's fundamental mechanisms deepens and more findings transition into targeted clinical treatments, the journal is structured around three main themes: Cancer Cell Biology, Tumorigenesis and Cancer Progression, and Translational Cancer Science. The current volume of this journal has transitioned from gated to open access through Annual Reviews' Subscribe to Open program, ensuring all articles are published under a CC BY license.
期刊最新文献
Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer Next-Generation Estrogen Receptor–Targeted Therapeutics Engineering the Immune Microenvironment into Organoid Models The Effects of Clonal Heterogeneity on Cancer Immunosurveillance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1